Cure development by FDG-PET and antiagent sensitivity in head and neck cancer
| Project/Area Number |
24791821
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Aichi Cancer Center Research Institute |
|---|
Principal Investigator |
SUZUKI Hidenori 愛知県がんセンター(研究所), 腫瘍病理学部, 研究員 (70470169)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 頭頸部外科 / FDG-PET / 抗がん剤感受性試験 / FDG-PET/CT / 抗癌剤感受性 / 予後予測 / 頭頸部癌 / Chemosensitivity / head and neck cancer |
|---|
| Outline of Final Research Achievements |
High 18F-FDG-uptake of primary tumor, assessed by pretreatment PET/CT,has indicated poor OS in HNC. We analyzed the relation between 18F-FDG-uptake and in vitro chemosensitivity of cisplatin using histoculture drug response assay in HNC. Twenty-eight patients were evaluated. SUVmax and I.I. cisplatin were calculated as 18F-FDG-uptake and in vitro chemosensitivity of cisplatin.Each SUVmax≧10.5 or I.I.cisplatin＜50 could significantly differentiate shorter survival group by OS analyses.I.I.cisplatin of patients with SUVmax≧10.5 was significantly greater. In 19 patients with SUVmax ≧ 10.5, those who received treatment with cisplatin-based chemotherapy exhibited a significant relation with longer OS.Cisplatin has the potential to improve OS for HNC that were predicted as shorter OS by 18F-FDG-PET/CT.
|
Report
(4 results)
Research Products
(16 results)
